Publications by authors named "S Perez-Torras"

Article Synopsis
  • YAT2150 is a new antimalarial drug that shows promise for malaria treatment and diagnosis by increasing fluorescence upon entering cells and blocking key developmental stages in malaria pathogens.
  • The drug's effective uptake mechanisms and favorable pharmacokinetics make it a strong candidate for enhancing transmission-blocking strategies, especially when used in conjunction with immunoliposome encapsulation to reduce toxicity.
  • YAT2150 interacts preferentially with unstructured proteins in parasites, which may lead to decreased protein aggregation, a mechanism also seen with traditional antimalarial treatments, positioning it as a potential leader in innovative malaria therapies.
View Article and Find Full Text PDF

Combined therapies play a key role in the fight against complex pathologies, such as cancer and related drug-resistance issues. This is particularly relevant in targeted therapies where inhibition of the drug target can be overcome by cross-activating complementary pathways. Unfortunately, the drug combinations approved to date -mostly based on small molecules- face several problems such as toxicity effects, which limit their clinical use.

View Article and Find Full Text PDF

Latanoprost (LAT) has been shown to have a hypertrichotic effect, which makes it a promising candidate for alopecia treatments. For the first time, LAT has been encapsulated in nanotransfersomes in order to increase its efficacy. skin biodistribution was studied by confocal laser microscopy both in human scalp and pig skin.

View Article and Find Full Text PDF

The proper regulation of nucleotide pools is essential for all types of cellular functions and depends on de novo nucleotide biosynthesis, salvage, and degradation pathways. Despite the apparent essentiality of these processes, a significant number of rare diseases associated with mutations in genes encoding various enzymes of these pathways have been already identified, and others are likely yet to come. However, knowledge on genetic alterations impacting on nucleoside and nucleobase transporters is still limited.

View Article and Find Full Text PDF

High-affinity uptake of natural nucleosides as well as nucleoside derivatives used in anticancer therapies is mediated by human concentrative nucleoside transporters (hCNTs). hCNT1, the hCNT family member that specifically transports pyrimidines, is also a transceptor involved in tumor progression. In particular, oncogenesis appears to be associated with hCNT1 downregulation in some cancers, although the underlying mechanisms are largely unknown.

View Article and Find Full Text PDF